
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
Optimizing process productivity, improving scalability and increasing efficiency are all important steps to developing a biopharmaceutical manufacturing process and high-performance Chinese Hamster Ovary (CHO) media feeds, supplements and kits can help developers achieve these goals.







